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Objective. About 70% of epithelial ovarian cancer patients (EOC) are diagnosed at advanced stage with a
ﬁve-year survival rate of only 30%. Whilst CA125 detects peritoneally-spread disease, it has limited sensitivity
for early cancers, many of which are potentially curable.
Methods. We compared the new commercially available tumor marker HE4 with CA125 individually, in
combination, within the risk of malignancy index (RMI) and the newly deﬁned risk of malignancy algorithm
(ROMA). Our prospectively-collected cohort of 160 patients consisted of healthy controls, benign diseases,
and borderline tumors/adenocarcinomas of ovarian, tubal, peritoneal and endometrial origin. HE4 and CA125
were measured in serum using standardized ELISA.
Results. Both markers showed similar diagnostic performance in the detection of EOC at clinically deﬁned
thresholds (CA125 35 U/ml; HE4 70 pM) but HE4 was not elevated in endometriosis. Comparison of non-
malignant diagnoses (n=71) versus early stage ovarian and tubal cancers (n=19) revealed that HE4 and
ROMA displayed the best diagnostic performance (AUC 0.86/0.87, speciﬁcity 85.9%/87.3% and sensitivity
78.9%/78.9%, respectively). Whilst RMICA125 detects peritoneal cancer better than all other models (AUC
0.99, speciﬁcity 97.2%, sensitivity 80.0%), there is no other detection beneﬁt from RMI compared to HE4 alone
or included in ROMA.
Conclusions. Themajor advantage of HE4 lies in its speciﬁcity and improved detection of borderline tumors
and early stage ovarian and tubal cancers. HE4 is superior to CA125 with or without RMI and ROMA indices.
However, we see no beneﬁt from combining both markers in clinical practice.
© 2011 Elsevier Inc. All rights reserved.
Introduction
Since its introduction CA125 has been the only clinically useful
tumor marker for the detection of epithelial ovarian cancers (EOC)
[1]. At present, the overall ﬁve-year survival for patients with EOC
is 40% due to 75% of patients being diagnosed as advanced stage
disease. In the absence of early detection markers, the risk of malig-
nancy index (RMI) is currently being used in combination with
CA125 [2]. Its fast and easy calculation enables gynecologists to
triage patients with probable EOC to specialized gynecological on-
cology centers [3].
As combined tumor markers might detect a larger fraction of early
FIGO stage EOC, several efforts have been undertaken to identify
adjuncts to CA125 [4–7]. HE4 (Human Epididymis 4) has evolved as a
promising marker identiﬁed during the genomic era [8] with several
studies reporting elevated mRNA expression of HE4 in various
subtypes of EOC [5–7,9–11] prompting investigations on its useful-
ness as a new tumor marker [10,12–22]. Whilst no study has exam-
ined the predictive value of HE4 within RMI, a recent publication has
proposed a new risk of malignancy algorithm (ROMA) which combi-
nes a logarithmical formula of HE4 levels with the menopausal status
[19].
With the increasing clinical availability of HE4, our aim was to
deﬁne the clinical beneﬁt gained by adding it to the present panel of
ovarian tumor markers. We measured the detection efﬁcacy of HE4
compared to CA125 within various risk indices with the aim to
identify clear beneﬁts compared to existing clinical alternatives. This
is therefore the ﬁrst study which measured and compared not only
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individual HE4 and CA125 detection rates within various gynecolog-
ical cancers but also their combination alone and in two clinically
available risk models, RMI and ROMA.
Materials and methods
ELISA
Patients admitted to the University Hospital Zurich were prospec-
tively included after giving informed consent in accordance with
ethical regulations (SPUK, Canton of Zurich, Switzerland). Patients
with a history of cancer or autoimmune diseaseswere excluded. Three
major patient groups were evaluated: 1. proven healthy patients
based on normal ﬁndings during surgery due to false ultrasonic
abnormalities or therapeutic procedures like tubal ligation; 2.
abnormalities/benign diseases diagnosed due to pathological CA125
levels or ultrasonic abnormalities like cystadenomas/adenoﬁbromas
or endometriosis; and 3. borderline tumors and adenocarcinomas of
ovarian, tubal, peritoneal or endometrial origin. All clinicopathological
patient data such as FIGO stage, grade, residual disease, presence of
ascites, past and present medical illness, ultrasonic ﬁndings and
outcome data were stored in a specially designed in-house database
(PEROV) based on ACCESS (Microsoft, USA). Histopathology of all
study patients were independently re-evaluated by a pathologist
specialized in the ﬁeld of gynecological oncology (R.C.), and patients
with unclear or mixed diagnoses were excluded from the study.
Blood samples were collected in EDTA blood tubes (BD Vacutainer®,
0184 M EDTA, BD Diagnostics, Franklin Lakes, NJ, USA) prior to surgery
and stored on ice until further processed. Samples were centrifuged at
4 °Cwithin 3 h at 3000×g for 10 min and supernatant stored at−80 °C.
ELISA for HE4 (Prod. Nr. 404–85; Fujirebio Diagnostics Inc., Goteborg,
Sweden) and CA125 were performed in a blinded customized fashion
(Fujirebio Diagnostics Inc., Goteborg, Sweden).
Statistical analysis
Serum values were calculated in units perml (U/ml) for CA125 and
in picomolar (pM) for HE4 and were additionally incorporated into
RMI (RMIHE4, RMICA125). RMI is calculated using the product of
serum CA125 level, ultrasound scan result (expressed as a score of 0, 1
or 3) and menopausal status (1, premenopausal and 3, postmeno-
pausal) [2]. An individual tumor marker combination (HE4×CA125)
was deﬁned as a product of absolute values of HE4 and CA125. These
were further combined by multiplication to standard RMI criteria
(RMIHE4×CA125). ROMA calculates the coefﬁcient for the natural log
(LN) of serum values and integrates it into a logistic regression for-
mula for pre-menopausal [Predictive Index (PI)=−12.0+2.38×LN
(HE4)+0.0626×LN(CA125)] and post menopausal [PI=−8.09+
1.04×LN(HE4)+0.732LN(CA125)] women [19].
All data analysis was performed using the open source statistical
programming language R (http://CRAN.R-project.org, version 2.8.1).
Each binary classiﬁer was analyzed by receiver operating character-
istics (ROC; R package ROCR) to determine its area under the curve
(AUC), sensitivity (Sens) deﬁned as true positive rate and speciﬁcity
(Spec) as true negative rate. The clinical thresholds for pathological
tumor marker values as deﬁned by the manufacturers were 35 U/ml
(CA125) and 70 pM (HE4). A suspiciousmass as deﬁned by RMICA125
showed a value of N200 arbitrary units (U) [2] and for HE4 (RMIHE4)
of N400 U. The threshold for the combination of both CA125 and HE4
was 2450 U (35 U/ml×70 pM) and within RMI (RMIHE4× CA125) as
14,000 U.
Results
Our cohort consisted of 160 patients divided into three indepen-
dent sub-groups, (1) thirty-three healthy controls, (2) seventy-one
patients with benign diseases, and (3) ﬁfty-six tumor patients. The
benign cohort consisted of cystadenomas (n=32), teratomas
(n=12) and endometriomas (n=20) whilst the tumor cohort
incorporated patients with ovarian and peritoneal borderline tumors
(n=8), endometrial cancers (n=5), adenocarcinoma of ovarian
(n=29), tubal (n=6) and peritoneal (n=5) origin and incidental
stromal tumors of the ovary (n=3) (Table 1, Table 2). Overall, there
were slightlymore pre- (n=84) than post-menopausal women in our
cohort (n=76) (Table 2).
Healthy controls and patients with benign diseases had low levels
for HE4 of 53 and 50 pM (interquartile range (IR) 39–62; 42–62,
respectively) as well as CA125 levels of 7 U/ml both (IR 4–12; 4–13,
respectively) (Fig. 1). The cancer cohort had a median concentration
of HE4 of 128 pM (IR 79–572) and for CA125 of 62 U/ml (IR 16–304).
Advanced peritoneal and tubal cancers had the highest median values
for both HE4 (411 pM, IR 193–1450; 703 pM, IR 127–2115, respec-
tively) and CA125 (2280 U/ml, IR 189–6390; 134 U/ml, IR 31–1330,
respectively) (Fig. 1). Patients with borderline tumors had a median
Table 1
Clinicopathological characteristics of the patient cohort (n=160).
Disease status n % Total
(%)
Healthy control (33) 33 100 20.6
Benign diseases (71) Simple cyst 4 5.6 44.4
Paratubarcyst 3 4.2
Cystadenoma/ﬁbroma 32 45.1
Endometriosis 10 14.1
Endometrioma 10 14.1
Teratoma 12 16.9
Borderline tumors and cancers (56) Borderline tumor 8 14.3 35.0
Epithelial ovarian cancer 29 51.8
Peritoneal cancer 5 8.9
Tubal cancer 6 10.7
Endometrium cancer 5 8.9
MMMT 2 3.6
Stromal sarcoma 1 1.8
Stage (56) I 15 26.8
II 10 17.8
III 21 37.5
IV 8 14.3
N/A 2 3.6
Grade (48) 1 5 10.4
2 15 31.1
3 26 54.2
N/A 2 4.3
Histotype (56) Serous 26 46.4
Endometrioid 13 23.2
Mucinous 6 10.7
Clear cell 2 3.6
Transitional cell 3 5.4
Others 6 10.7
Table 2
Clinical and biochemical characteristics of the patient cohort (n=160).
Disease status Patients
(%)
Non-malignant Borderline/malignant
Age (years) b50 51 10 61 (38.1)
≥50 53 46 99 (61.9)
Menopausal status pre 62 22 84 (52.5)
post 42 34 76 (47.5)
CA125 [U/ml] b35 96 24 120 (75.0)
≥35 8 32 44 (25.0)
HE4[pM] b70 89 13 102 (63.7)
≥70 15 43 58 (36.3)
ROMA (%) b13.1 89 11 100 (62.5)
≥13.1 15 45 60 (37.5)
RMICA125 (U) b200 101 22 123 (76.9)
≥200 3 34 37 (23.1)
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value close to the detection threshold of 77 pM (HE4, IR 59–96)
and 14.4 U/ml (CA125, IR 9–20) (Fig. 1). Patients with endometrial
cancers did not have abnormal levels of HE4 (58 pM, IR 47–61) or
CA125 (3 U/ml, IR 3–14) (Fig. 1) and failed to be detectable with any
model indicated by low AUC (range 0.03–0.54), speciﬁcity (78.8–
97.2%) and sensitivity (0–40.0%). Endometrial cancers were therefore
not included in further speciﬁc comparisons.
ROC analysis of individual tumor markers and their combinations
were performed for the whole patient cohort (non-malignant
(n=104) versus malignant (n=48)) and revealed similar high AUC
values for all calculated models (range 0.87–0.95). HE4 performed
best (Spec 84.6%; Sens 83.3) with only a slightly better result within
ROMA (Spec 85.6%; Sens 85.4) (Table 3). HE4 and ROMA showed an
improved speciﬁcity when the borderline/cancer cohort was com-
pared to benign diseases (85.9%/87.3%, respectively) instead of
healthy controls (81.8%/78.8%, respectively). We also compared
endometriosis (n=20) to the borderline/cancer group (n=48)
which revealed the best performance using ROMA (AUC 0.89,
Fig. 1. Marker distribution. Boxplots of HE4 and CA125 levels alone and combined in RMI; black dotted line indicates threshold to separate non-malignant conditions from EOC.
Table 3
Receiver operator curves on selected biomarker models. Area under the curve (AUC), speciﬁcity (Spec, in %), sensitivity (Sens, in %) revealed by comparison of healthy controls,
benign diseases, endometriosis (EM) or whole non-malignant group versus borderline tumors (BL), epithelial ovarian (EOC), peritoneal (PC), tubal (TC) and endometrial cancers
(EC). Threshold: HE4 70 pM; CA125 35 U/ml; HE4⁎CA125 2450 U; ROMA 13.1%; RMIHE4 400 U; RMICA125 200 U; RMIHE4⁎CA125 14,000 U.
Versus HE4 CA125 CA125⁎HE4 ROMA RMIHE4 RMICA125 RMICA125⁎HE4
AUC Spec Sens AUC Spec Sens AUC Spec Sens AUC Spec Sens AUC Spec Sens AUC Spec Sens AUC Spec Sens
Healthy controls EOC 0.92 81.8 86.2 0.92 93.9 67 0.95 97 82.8 0.92 81.8 89.6 0.97 93.9 89.6 0.97 93.9 75.9 0.98 100 86.2
BL 0.81 62.5 0.72 12.5 0.79 93.9 25 0.79 78.8 62.5 0.89 50 0.91 37.5 0.92 97 37.5
PC 0.80 80 0.97 80 0.87 80 0.82 80 0.92 80 0.99 80 0.97 80
TC 1.00 100 0.85 66.7 0.95 66.7 0.98 100 0.97 66.7 0.85 100 50 0.97 66.7
EC 0.53 0 0.39 0 0.38 0 0.44 40 0.25 0 0.26 93.9 0 0.25 0
I/II+BL 0.86 78.9 0.79 36.8 0.85 52.6 0.85 78.9 0.92 63.1 0.94 47.4 0.95 100 63.2
III/IV 0.93 89.3 0.95 78.6 0.96 97 85.7 0.94 81.8 92.8 0.98 92.8 0.98 82.1 0.98 97 85.7
Benign disease EOC 0.91 85.9 86.2 0.89 90.1 69 0.93 92.9 82.8 0.93 87.3 89.6 0.94 83.1 89.6 0.96 98.6 75.7 0.96 97.2 86.2
BL 0.83 62.5 0.67 12.5 0.76 25 0.83 62.5 0.83 50 0.82 97.2 25 0.86 37.5
PC 0.80 80 0.96 80 0.86 80 0.82 80 0.89 80 0.99 80 0.94 95.8 80
TC 0.99 100 0.83 66.7 0.93 66.7 0.98 100 0.93 66.7 0.92 66.7 0.97 66.7
EC 0.54 0 0.38 0 0.37 0 0.45 40 0.03 0 0.03 0 0.03 0
I/II+BL 0.86 78.9 0.76 36.8 0.83 52.6 0.87 78.9 0.87 63.2 0.89 47.4 0.90 97.2 63.2
III/IV 0.93 89.3 0.94 78.6 0.95 85.7 0.94 92.8 0.95 92.8 0.98 98.6 82.1 0.98 89.3
EM Cancer+BL 0.89 80 83.3 0.76 80 60.4 0.84 90 71 0.89 80 85.4 0.96 100 79.2 0.92 100 66.7 0.93 100 75
Non-malignant Cancer+BL 0.89 84.6 83.3 0.87 91.3 60.4 0.90 94.2 70.8 0.90 85.6 85.4 0.93 86.5 79.1 0.95 97.1 66.7 0.95 98.1 75
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speciﬁcity 80.0% and sensitivity 85.4%) followed by HE4 with equal
AUC value and speciﬁcity but less sensitivity (83.3%) (Table 3).
Borderline tumors were best detected using HE4 alone compared
to the group of healthy control or benign disease with a AUC of 0.81/
0.83, speciﬁcities of 81.8%/85.9% and sensitivities of 62.5%/62.5%,
respectively (Fig. 2). ROMA performed similar to HE4 with AUC of
0.79/0.83, speciﬁcities of 78.8%/87.3% and sensitivities of 62.5%/62.5%.
The lowest sensitivity in the detection of borderline tumors from
healthy controls or patients with benign diseases could be found for
CA125 (AUC 0.72/0.67, speciﬁcity 93.9%/90.1%, sensitivity 12.5%/
12.5%).
All models revealed the same sensitivity of 80.0% for comparison of
healthy controls/benign diseases and peritoneal cancers but RMI-
CA125⁎HE4 detected it best (AUC 0.97/0.94, speciﬁcity 97.0%/95.8%;
Fig. 2). HE4 and ROMA revealed here theworst performancewith AUC
of 0.80/0.82 and speciﬁcity reduced by about 10%–15% compared to
CA125 alone (Table 3).
The ability to detect early cancers would deﬁnitely improve
patient prognosis. Therefore, we studied HE4 and CA125 detection
rates for FIGO Stage I and II borderline tumors (3 mucinous, 4 serous
and ovarian/tubal cancers of serous (n=4), endometrioid (n=4),
mucinous (n=3) and transitional cell (n=1) subtypes. The best
detection compared to healthy controls (n=33) or benign diseases
(n=71) was achieved with ROMA (AUC 0.85/0.87, respectively) and
HE4 (AUC 0.86/0.86, respectively) (Table 3).
Conclusion
Emerging from the genomic era, HE is the most prominent and
second commercially available tumor marker for EOC. Recent studies
observed a better diagnostic performance of HE4 compared to CA125
(Table 4), however, it is difﬁcult to directly compare these publica-
tions because the detection threshold has been variable and cancer
sensitivity and speciﬁcity was measured either in relation to benign
diseases or healthy controls (Table 4). We ensured that only indivi-
duals with proven negative operative ﬁndings were included as
healthy controls to exclude cases of asymptomatic endometriosis or
pelvic inﬂammatory disease. Indeed we were able to show that
healthy controls and benign diseases differ slightly and if pooled
together can inﬂuence the diagnostic performance rate in comparison
to cancers.
Our data support an advantage of HE4 over CA125 mainly in the
detection of ovarian borderline tumors and early stage epithelial
ovarian [19] and tubal cancers. The similar expression proﬁle of both
markers accounts for the ﬁnding that additional risk indices have not
improved the detection rate more than a few percent. The combi-
nation of both markers (HE4⁎CA125, ROMA, RMIHE4⁎CA125) does
not improve the diagnostic performance of HE4 alone and does not
overcome the inability of both markers to adequately detect early
stage epithelial ovarian cancers, with or without RMI or ROMA. The
only potential beneﬁt we see from a combination of CA125 with HE4
would be in a premenopausal woman with a high RMI due to an
elevated CA125. A normal HE4 value in this situation would imply
rather the differential diagnosis of a benign endometrioma [19] than
ovarian cancer and this patient could therefore be operated laparos-
copically by a gynecologist.
If there would be a conjoint decision to use HE4 as new tumor
marker for ovarian, tubal and peritoneal cancers and was similarly
available, it would have clear beneﬁts for the detection of these
diseases. However, as long as CA125 is still widely used, the urge to
simultaneously measure both markers will cause an unnecessary rise
in costs for minimal beneﬁts. Currently, HE4 is available for double the
price of CA125, but the combination of both markers will triple the
costs. Moreover, screening measurements of tumor markers in
nonsymptomatic women is clearly not justiﬁed and has not proven
any beneﬁt in early detection, let alone by a combination of markers
involving CA19-9, CEA and CA72-4 to include mucinous tumors.
Testing for both HE4 and CA125, alone or combined with any clinical
risk assessment, is therefore not advisable for clinical routine.
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Benign vs. EOC 84.6/75.0 94.3/75.0
Benign vs. early stage EOC n/a n/a 64.7/75.0 85.3/75.0
Benign vs. late stage EOC 93.0/75.0 98.8/75.0
RMI ROMA
Montagnana et al. [16] CA125 (37 U/ml); Healthy vs. EOC 83/100 98/100 n/a
HE4 (30 pmol/l)
Shah et al. [22] Speciﬁcity of 95% Healthy average risk vs. EOC 79.4/95.0 80.4/95.0 53.9/95.0
Healthy high risk vs. EOC 82.9/95.0 87.8/95.0 39.0/95.0
Benign average risk vs. EOC 58.8/95.0 61.8/95.0 43.1/95.0
Benign high risk vs. EOC 63.4/95.0 75.6/95.0 34.1/95.0
Mesothelin
Huhtinen et al. [15] Speciﬁcity of 95% Endometriosis vs. EOC 64.3/95.0 71.4/95.0 78.6/95.0
Healthy vs. EOC 78.6/95.0 78.6/95.0 92.9/95.0
Endometriosis vs. healthy 60.9/95.0 05.8/95.0 62.3/95.0
CA125+HE4
Moore et al. [20] Predictive probability
(PP) threshold 13.1%
Benign vs. cancera n/a n/a 88.7/74.7
Benign vs. cancera (premeno) 76.5/74.8
Benign vs. cancera (postmeno) 92.3/74.7
ROMA
Andersen et al. [13] Upper 95th percentile
of the benign groups
Healthy vs. EOC 81.1/94.9 77.0/94.6 63.5/88.3
Healthy vs. EOC (b50 years) 83.3/90.9 83.3/100 83.3/90.0
Healthy vs. EOC (N50 years) 81.4/96.3 76.3/93.6 57.6/89.0
Symptom Index (SI)
Moore et al. [17] Speciﬁcity of 95% Healthy vs. EC 24.6/95.0 45.5/95.0 50.1/95.0
Healthy vs. stage I EC 20.8/95.0 37.9/95.0 41.7/95.0
Moore et al. [18] Speciﬁcity of 95% Benign vs. EOC 43.3/95.0 72.9/95.0 76.4/95.0 (CA125+HE4)
79.1/95.0 (CA125+HE4+
CA72-4+mesothelin+
osteopontin)
Havrilesky et al. [14] Best cutoff (BC);
mean+2SD (2SD)
Healthy vs. early stage EOC (BC) 45.9/98.2 82.7/86.3 80.5/96.5
Healthy vs. late stage EOC (BC) 58.5/98.2 92.5/86.3 89.2/97.2
Healthy vs. early stage EOC (2SD) 45.9/98.5 62.4/96.0 CA125+HE4+Glyco-delin+
Plau-R+MUC1+PAI-1 (BC)Healthy vs. late stage EOC (2SD) 58.5/98.5 74.6/96.0
Hellstrom et al. [10] Speciﬁcity of 96% Benign/healthy vs. EOC 40.0/96.0 67.0/96.0 n/a
Benign/healthy vs. early stage EOC 71.0/96.0 86.0/96.0
Benign/healthy vs. late stage EOC 80.0/96.0 80.0/96.0
a Deﬁned as EOC, OBL, non-EOC, metastatic and other gynecological cancers.
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